FHTX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
83.5M
+419.8%
16.1M
+391.9%
3.3M
-64.7%
9.2M
+13.4%
8.2M
Cost of Revenue
0
0
0
0
0
Gross Profit
83.5M
+419.8%
16.1M
+391.9%
3.3M
-64.7%
9.2M
+13.4%
8.2M
Operating Expenses
26.9M
+8.1%
24.9M
+0.1%
24.8M
-25.0%
33.1M
+24.3%
26.7M
R&D
18.8M
+1.7%
18.5M
+1.4%
18.3M
-17.2%
22.0M
+10.2%
20.0M
SG&A
5.8M
-8.8%
6.4M
-3.4%
6.6M
-3.2%
6.8M
+2.2%
6.7M
Operating Income
56.6M
+743.3%
-8805000
+59.2%
-21573000
+9.7%
-23878000
-29.1%
-18501000
EBITDA
59.1M
+789.5%
-8575000
+59.8%
-21335000
-24.3%
-17162000
+2.8%
-17649000
Net Income
58.1M
+908.6%
-7191000
+63.8%
-19875000
+8.3%
-21664000
-36.7%
-15849000
EPS (Basic)
$0.81
+910.0%
$-0.10
+65.5%
$-0.29
+14.7%
$-0.34
-36.0%
$-0.25
EPS (Diluted)
$0.80
+900.0%
$-0.10
+65.5%
$-0.29
+14.7%
$-0.34
-36.0%
$-0.25
Shares (Diluted)
72.6M
+2.8%
70.6M
+1.6%
69.5M
+10.3%
63.1M
+0.1%
63.0M
Foghorn Therapeutics (FHTX) — Financials